Patients with asthma or COPD who used semaglutide for type 2 diabetes experienced significant reductions in their exacerbations, according to an abstract presented at the European Respiratory Society International Congress.
Exenatide and dulaglutide were associated with reductions in exacerbations as well, Chloe I. Bloom, MBChB, PhD, MSc, clinical associate professor in respiratory epidemiology, National Heart and Lung Institute, Imperial College London, and colleagues wrote.
“Conditions such as type 2 diabetes and excess weight are very common in people with asthma and COPD and are linked to